Michael Mortimore

机构：Vertex Pharmaceuticals (United Kingdom), Vertex Pharmaceuticals (United States)

发表论文 26 篇 · 总被引 1556 次 · h-index 16

代表论文

• Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents (2011 · Journal of Medicinal Chemistry · 被引 264)
• From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis (2007 · Bioorganic & Medicinal Chemistry Letters · 被引 236)
• Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents (2009 · Journal of Medicinal Chemistry · 被引 181)
• Biogenetically Inspired Approach to the Strychnos Alkaloids. Concise Syntheses of (±)-Akuammicine and (±)-Strychnine (2001 · Journal of the American Chemical Society · 被引 164)
• Characterization of a selective and potent antagonist of human P2X7receptors, AZ11645373 (2006 · British Journal of Pharmacology · 被引 135)
• The discovery of the potent aurora inhibitor MK-0457 (VX-680) (2009 · Bioorganic & Medicinal Chemistry Letters · 被引 101)